Study register / Autonomic / Other / Atopic Dermatitis

Atopic Dermatitis

2 curated studies · 2 key studies · mechoulam.de

Early small controlled trials on cannabidiol-containing skin preparations for atopic dermatitis report a relief of itching and skin findings. These are short studies using combination products. Larger confirmatory trials are still awaited.

Rating scheme

The letter rates the quality of a study, independently of its type. Every study type can receive any grade: a review can be B or C when it is small or weak, and an RCT can be S. The grade is a synthesis of study design, journal authority and clinical bindingness:

S
Highest evidence, large, methodologically first-rate studies or S3 guidelines
A
Strong evidence, solid, meaningful studies with a clear result
B
Moderate evidence, smaller or methodologically limited studies
C
Weak evidence, preliminary, indirect or contradictory findings
D
Lowest evidence, exploratory hints, single cases or expert opinion

Quality profile per study

To the left of each study there is a profile of four features, it shows the differences within a letter class.

Sample size ★
Number of participants (RCT) or included studies (review).
Blinding
Double-blind, single-blind or open-label.
Effect size
Clear benefit, mixed, no benefit or harm.
Citations / year ★
Age-adjusted citation frequency.

Key studies

2
  1. 01
    B
    Novel cannabidiol aspartame combination treatment (JW-100) significantly reduces ISGA score in atopic dermatitis: Results from a randomized double-blinded placebo-controlled interventional study.
    Gao et al. ·2022 ·Journal of cosmetic dermatology
    Read
  2. 02
    B
    An oil-in-water emulsion containing a combination of ginger extract and synthetic cannabidiol with potent in vitro anti-inflammatory effects alleviates symptoms of atopic dermatitis in a clinical trial.
    Neubauer et al. ·2024 ·European journal of dermatology
    Read

Randomised Controlled Trials

Efficacy and safety evidence from controlled interventional trials.

2
B
Sample size ★★★★★
Blinding —
Effect size —
Citations / year —
● Key study
Gao et al. ·2022 ·Journal of cosmetic dermatology

Novel cannabidiol aspartame combination treatment (JW-100) significantly reduces ISGA score in atopic dermatitis: Results from a randomized double-blinded placebo-controlled interventional study.

Design
RCT
Sample
n = 57 Pat.
Summary

Double-blind, placebo-controlled RCT with n=57 AD patients, three groups: JW-100 (CBD + aspartame), CBD alone, placebo over 14 days. ISGA score reduction: JW-100 -1,28 (p=0,042), CBD -0,81, placebo -0,71. 50% of the JW-100 group achieved ISGA 0-1 with ≥2-grade improvement (p=0,028) vs. 20% (CBD) and 15% (placebo).

DOI 10.1111/jocd.14263 ↗
B
Sample size ★★★★★
Blinding —
Effect size Clear benefit
Citations / year ★★★★★
● Key study
Neubauer et al. ·2024 ·European journal of dermatology
3 citations

An oil-in-water emulsion containing a combination of ginger extract and synthetic cannabidiol with potent in vitro anti-inflammatory effects alleviates symptoms of atopic dermatitis in a clinical trial.

Design
RCT
Sample
n = 44 Pat.
Key finding

BNO 3731 significantly reduced itch intensity by 55% and improved AD symptoms as well as physiological skin parameters; in 75% of patients itch improved by ≥2 points on the NRS-11 scale.

Summary

RCT with n=44 AD patients (adults + children), topical BNO 3731 (ginger extract + synthetic CBD) vs. benchmark over 5 days. Itch intensity decreased significantly by 55%, in 75% of subjects improvement ≥2 points on the NRS-11 scale. Significant improvement in objective and subjective dermatological parameters as well as physiological skin parameters. No adverse events.

DOI 10.1684/ejd.2024.4738 ↗

Ongoing and upcoming studies

Ongoing studies are still in the trial phase and are not evidence of efficacy or safety. The information serves educational purposes only.

1
  • NCT00605878 ClinicalTrials.gov Studies of Skin Microbes in Healthy People and in People With Skin Conditions Recruiting Start: 2008-01